Pharmidex partners in European Commission H2020 award
May 21, 2017

Pharmidex joins Horizon 2020 EU project to work on radioactive contamination

Pharmidex partners in European Commission H2020 award

This project aims to stimulate intersectoral and international collaboration within Europe and with an ICPC country, Kazakhstan, in the area of novel nanoporous and nanostructured adsorbents for the treatment of very serious health conditions associated with acute and chronic exposure to external radiation and uptake of heavy metals and radiation as a consequence of accidental, occupational or deliberate activities and events.


This can dramatically lower the quality of life of the people affected and at present the treatment available is costly and inefficient. Radioactive contamination is a particularly serious problem in two of the countries participating in this project, namely, Ukraine and Kazakhstan, on large territories of the Chernobyl zone and around Semipalatinsk nuclear test site, respectively.


A large number of people are affected by living in the areas with elevated level of radioactivity with uncertain long-term consequences to their health and the health of future generations.


The expected impact of the project results is development of efficient and cost-effective methods of protection of first responders, population and cancer patients treated with radiotherapy from elevated doses of external and incorporated radiation and for occupational health protection of personnel working and the population living in areas contaminated with heavy metals.


Please find more information on the following web page: http://cordis.europa.eu/project/rcn/207057_en.html

April 15, 2026
Pharmidex will be attending Swiss Biotech Day 2026 on 4–5 May 2026 at the Congress Center Basel, Switzerland. We look forward to meeting founders, investors, biotech leaders and scientific partners to discuss drug discovery, translational development and strategic R&D opportunities. Feel free to catch us for a chat!
April 9, 2026
Pharmidex partners with Data Sciences International (DSI) to utilise industry-leading whole body plethysmography (WBP) systems, incorporating the patented Halcyon® pneumotach noise suppression technology. This enables the delivery of high-quality preclinical respiratory studies with enhanced clarity, sensitivity and confidence. By leveraging the robustness of DSI’s WBP platform alongside Pharmidex’s scientific expertise, we offer well-characterised models to assess: • Cough responses • Hypercapnic challenge responses • Functional respiratory changes across disease states such as asthma This integrated approach supports reliable and translatable assessment of airway function, disease progression and therapeutic efficacy, helping to de-risk programmes and drive better decision-making in preclinical development. Always keen to hear how others are advancing respiratory endpoints in their studies.
April 1, 2026
We’re pleased to share that Pharmidex has been selected as a partner in the EIC - European Innovation Council Ecosystem Partnership Programme. Our services are now featured on the EIC Service Catalogue, making them accessible to innovative companies and projects supported by the EIC across Europe. This is a great opportunity to further support cutting-edge biotech and life sciences programmes by providing: ๐Ÿ”ฌ Preclinical in vivo pharmacology ๐Ÿงช Bioanalysis (LC–MS/MS, qPCR, ELISA) ๐Ÿ“Š Translational and mechanistic studies ๐Ÿงซ Histology and pathology We look forward to working with EIC beneficiaries and contributing to the development of the next generation of therapies. If you are part of the EIC ecosystem and looking for a flexible, science-led CRO partner, we would be delighted to connect.
More Posts